litlas
Log inCreate account

Peter Hersey

Active 1973–2024

145
Papers
34,649
Citations
93
h-index
144
i10-index

Citations

Citations per year for Peter Hersey1974: 3 citations1975: 2 citations1976: 4 citations1977: 5 citations1978: 4 citations1979: 2 citations1980: 4 citations1981: 6 citations1982: 10 citations1983: 8 citations1984: 8 citations1985: 13 citations1986: 12 citations1987: 16 citations1988: 8 citations1989: 18 citations1990: 21 citations1991: 6 citations1992: 12 citations1993: 12 citations1994: 12 citations1995: 25 citations1996: 29 citations1997: 31 citations1998: 35 citations1999: 74 citations2000: 90 citations2001: 135 citations2002: 100 citations2003: 151 citations2004: 140 citations2005: 124 citations2006: 104 citations2007: 152 citations2008: 171 citations2009: 140 citations2010: 153 citations2011: 166 citations2012: 266 citations2013: 508 citations2014: 597 citations2015: 645 citations2016: 477 citations2017: 565 citations2018: 544 citations2019: 1,434 citations2020: 1,362 citations2021: 1,180 citations2022: 936 citations2023: 583 citations2024: 807 citations2025: 340 citations2026: 11 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,386 citing papers, 28.3% of this breakdownChina: 1,490 citing papers, 9.6% of this breakdownAustralia: 968 citing papers, 6.3% of this breakdownUnited Kingdom: 907 citing papers, 5.9% of this breakdownGermany: 835 citing papers, 5.4% of this breakdownItaly: 823 citing papers, 5.3% of this breakdownFrance: 708 citing papers, 4.6% of this breakdownNetherlands: 482 citing papers, 3.1% of this breakdownCanada: 459 citing papers, 3% of this breakdownJapan: 426 citing papers, 2.7% of this breakdownSwitzerland: 390 citing papers, 2.5% of this breakdownSpain: 389 citing papers, 2.5% of this breakdown
0%28.3%Other 20.8%

Institutions

Fields

  • Medicine54.3%
  • Biochemistry, Genetics and Molecular Biology32.7%
  • Immunology and Microbiology9.7%
  • Engineering0.8%
  • Computer Science0.4%
  • Neuroscience0.4%
  • Other1.7%

Topics

  • Cancer Immunotherapy and Biomarkers11.8%
  • Immunotherapy and Immune Responses7%
  • Melanoma and MAPK Pathways6.8%
  • CAR-T cell therapy research5.2%
  • Cutaneous Melanoma Detection and Management5.2%
  • Immune Cell Function and Interaction3.2%
  • Other60.8%

Coauthors

All papers

Open in search
  1. Whole-genome landscapes of major melanoma subtypes

    Authors: Nicholas K. Hayward, James S. Wilmott, Nicola Waddell, Peter A. Johansson, Matthew A. Field, Kátia Nones, Ann‐Marie Patch, Hojabr Kakavand, Ludmil B. Alexandrov, Hazel Burke, Valerie Jakrot, Stephen H. Kazakoff, Oliver Holmes, Conrad Leonard, Radhakrishnan Sabarinathan, Loris Mularoni, Scott Wood, Qinying Xu, Nick M. Waddell, Varsha Tembe, Gulietta M. Pupo, Ricardo De Paoli‐Iseppi, Ricardo E. Vilain, Ping Shang, Loretta M. S. Lau, Rebecca A. Dagg, Sarah‐Jane Schramm, Antonia L. Pritchard, Ken Dutton‐Regester, Felicity Newell, Anna Fitzgerald, Catherine A. Shang, Sean M. Grimmond, Hilda A. Pickett, Jean Yang, Jonathan R. Stretch, Andreas Behren, Richard Kefford, Peter Hersey, Georgina V. Long, Jonathan Cebon, Mark Shackleton, Andrew J. Spillane, Robyn P.M. Saw, Núria López-Bigas, John V. Pearson, John F. Thompson, Richard A. Scolyer, Graham J. Mann - Nature 2017 cited by 1,522

  2. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

    Authors: Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen‐Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Mitchell, Amita Patnaik, Hassane M. Zarour, Anthony M. Joshua, Qi Zhao, E. Jensen, S. Ahsan, Nageatte Ibrahim, Antoni Ribas - Annals of Oncology 2019 cited by 944

  3. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Authors: Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Gangadhar, Amita Patnaik, Hassane M. Zarour, Anthony M. Joshua, Kevin Gergich, Jeroen Elassaiss‐Schaap, Alain P. Algazi, Christine Mateus, Peter D. Boasberg, Paul C. Tumeh, Bartosz Chmielowski, Scot Ebbinghaus, Xiaoyun Li, Sunyu Kang, Antoni Ribas - New England Journal of Medicine 2013 cited by 3,395

  4. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Authors: Keith T. Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter Mohr, Reinhard Dummer, Uwe Trefzer, James Larkin, Jochen Utikal, Brigitte Dréno, Marta Nyakas, Mark R. Middleton, Jürgen C. Becker, Michelle Casey, Laurie Sherman, Frank Wu, Danièle Ouellet, Anne‐Marie Martin, Kiran Klaus Patel, Dirk Schadendorf - New England Journal of Medicine 2012 cited by 2,141

  5. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Authors: Antoni Ribas, Omid Hamid, Adil Daud, F. Stephen Hodi, Jedd D. Wolchok, Richard Kefford, Anthony M. Joshua, Amita Patnaik, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Peter Hersey, Roxana Dronca, Richard W. Joseph, Hassane M. Zarour, Bartosz Chmielowski, Donald P. Lawrence, Alain P. Algazi, Naiyer A. Rizvi, Brianna Hoffner, Christine Mateus, Kevin Gergich, Jill A. Lindia, Maxine Giannotti, Xiaoyun Li, Scot Ebbinghaus, Soonmo Peter Kang, Caroline Robert - JAMA 2016 cited by 1,062

  6. CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment

    Authors: Jarem Edwards, James S. Wilmott, Jason Madore, Tuba N. Gide, Camelia Quek, Annie Tasker, Angela L. Ferguson, Jinbiao Chen, Rehana Hewavisenti, Peter Hersey, Thomas Gebhardt, Wolfgang Weninger, Warwick J. Britton, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, Umaimainthan Palendira - Clinical Cancer Research 2018 cited by 441

  7. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci and 32 more - The Lancet Oncology 2021 cited by 389

  8. Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

    Authors: Adil Daud, Jedd D. Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S. Weber, Antoni Ribas, F. Stephen Hodi, Anthony M. Joshua, Richard Kefford, Peter Hersey, Richard W. Joseph, Tara C. Gangadhar, Roxana Dronca, Amita Patnaik, Hassane M. Zarour, Charlotte Roach, Grant Toland, Jared Lunceford, Xiaoyun Li, Kenneth Emancipator, Marisa Dolled‐Filhart, Sunyu Kang, Scot Ebbinghaus, Omid Hamid - Journal of Clinical Oncology 2016 cited by 678

  9. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

    Authors: Mark B. Faries, John F. Thompson, Alistair J. Cochran, Robert H.I. Andtbacka, Nicola Mozzillo, Jonathan S. Zager, Tiina Jahkola, Tawnya L. Bowles, Alessandro Testori, Peter D. Beitsch, Harald J. Hoekstra, Marc Moncrieff, Christian Ingvar, Michel W.J.M. Wouters, Michael S. Sabel, Edward A. Levine, Doreen M. Agnese, Michael A. Henderson, Reinhard Dummer, Carlo Riccardo Rossi, Rogerio I. Neves, Steven D. Trocha, Frances C. Wright, David R. Byrd, Maurice Matter, Eddy C. Hsueh, Alastair D. MacKenzie Ross, Douglas B. Johnson, Patrick Terheyden, Adam C. Berger, Tara L. Huston, Jeffrey D. Wayne, B. Mark Smithers, Heather B. Neuman, Schlomo Schneebaum, Jeffrey E. Gershenwald, Charlotte E. Ariyan, Darius C. Desai, Lisa K. Jacobs, Kelly M. McMasters, Anja Gesierich, Peter Hersey, Steven D. Bines, John M. Kane, Richard J. Barth, Gregory McKinnon, Jeffrey M. Farma, Erwin Schultz, Sergi Vidal‐Sicart, Richard Hoefer, James M. Lewis, Randall P. Scheri, Mark C. Kelley, Omgo E. Nieweg, R. Dirk Noyes, Dave S.�B. Hoon, He-Jing Wang, David Elashoff, Robert M. Elashoff - New England Journal of Medicine 2017 cited by 1,385

  10. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Authors: Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, René González, Anna C. Pavlick, Jeffrey S. Weber, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Peter Hersey, Richard Kefford, Donald P. Lawrence, Igor Puzanov, Karl D. Lewis, Ravi K. Amaravadi, Bartosz Chmielowski, H. Jeffrey Lawrence, Yu Shyr, Fei Ye, Jiang Li, K. B. Nolop, Richard J. Lee, Andrew K. Joe, Antoni Ribas - New England Journal of Medicine 2012 cited by 2,148

  11. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

    Authors: Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D. Wolchok, Anthony M. Joshua, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard W. Joseph, Roxana Dronca, Amita Patnaik, Hassane M. Zarour, Richard Kefford, Peter Hersey, Jin Zhang, James R. Anderson, Scott J. Diede, Scot Ebbinghaus, F. Stephen Hodi - Journal of Clinical Oncology 2017 cited by 482

  12. Guidelines for the use of platelet transfusions

    Authors: Lise J Estcourt, Janet Birchall, Shubha Allard, Stephen J. Bassey, Peter Hersey, Jonathan P. Kerr, Andrew Mumford, Simon Stanworth, Hazel Tinegate - British Journal of Haematology 2016 cited by 626

  13. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

    Authors: Caroline Robert, Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, Adil Daud, F. Stephen Hodi, Jedd D. Wolchok, Tara C. Mitchell, Peter Hersey, Roxana Dronca, Richard W. Joseph, C. Boutros, Le Min, Georgina V. Long, Jacob Schachter, Igor Puzanov, Reinhard Dummer, Jianxin Lin, Nageatte Ibrahim, Scott J. Diede, Matteo S. Carlino, Anthony M. Joshua - European Journal of Cancer 2020 cited by 100

  14. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

    Authors: James S. Wilmott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghwa Sharma, John F. Thompson, Richard Kefford, Peter Hersey, Richard A. Scolyer - Clinical Cancer Research 2011 cited by 650

  15. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

    Authors: Richard W. Joseph, Jeroen Elassaiss‐Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, Soonmo Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar - Clinical Cancer Research 2018 cited by 309

  16. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Brigitte Dréno, John F Thompson, B. Mark Smithers, Mario Santinami, Thomas Jouary, Ralf Gutzmer, E. Levchenko, Piotr Rutkowski, Jean-Jacques Grob, S.I. Korovin, Kamil Drucis, Florent Grange, L. Machet, Peter Hersey, Ivana Krajsová, Alessandro Testori, Robert M. Conry, B. Guillot, Wim H.J. Kruit, Lev Demidov, John A. Thompson, Igor Bondarenko, Jarosław Jaroszek, Susana Puig, Gabriela Cinat, Axel Hauschild, Jelle J. Goeman, Hans C. van Houwelingen, Fernando Ulloa-Montoya, Andrea Callegaro, Benjamin Dizier, Bart Spiessens, Muriel Debois, Vincent Brichard, Jamila Louahed, Patrick Therasse, C. Debruyne, John M. Kirkwood - The Lancet Oncology 2018 cited by 198

  17. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

    Authors: C. Owen, Alexander N. Shoushtari, D Chauhan, David Palmieri, Belinda Lee, Maartje W. Rohaan, Joanna Mangana, Victoria Atkinson, Farzana Y. Zaman, Arissa Young, Christoph Höeller, Peter Hersey, R. Dummer, Muhammad A. Khattak, Michael Millward, Sapna P. Patel, Andrew Haydon, Douglas B. Johnson, Serigne Lo, Christian U. Blank, Shahneen Sandhu, Matteo S. Carlino, James Larkin, Alexander M. Menzies, Georgina V. Long - Annals of Oncology 2020 cited by 110

  18. Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

    Authors: Kavitha Gowrishankar, Dilini Gunatilake, Stuart Gallagher, Jessamy Tiffen, Helen Rizos, Peter Hersey - PLoS ONE 2015 cited by 222

  19. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

    Authors: Abdullah Al Emran, Aniruddha Chatterjee, Euan J. Rodger, Jessamy Tiffen, Stuart Gallagher, Michael R. Eccles, Peter Hersey - Trends in Immunology 2019 cited by 215

  20. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

    Authors: F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jeffrey S. Weber, Adil Daud, Omid Hamid, Amita Patnaik, Antoni Ribas, Caroline Robert, Tara C. Gangadhar, Anthony M. Joshua, Peter Hersey, Roxana Dronca, Richard W. Joseph, Darcy A. Hille, Dahai Xue, Xiaoyun Li, Sunyu Kang, Scot Ebbinghaus, Andrea Perrone, Jedd D. Wolchok - Journal of Clinical Oncology 2016 cited by 751

  21. PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials

    Authors: Jason Madore, Ricardo E. Vilain, Alexander M. Menzies, Hojabr Kakavand, James S. Wilmott, Jessica Hyman, Jennifer H. Yearley, Richard Kefford, John F. Thompson, Georgina V. Long, Peter Hersey, Richard A. Scolyer - Pigment Cell & Melanoma Research 2014 cited by 392

  22. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

    Authors: Peter Hersey, Jeffrey A. Sosman, Steven O’Day, Jon Richards, Agop Y. Bedikian, René González, William H. Sharfman, Robert Weber, Theodore F. Logan, Manuela Buzoianu, Luz Hammershaimb, John M. Kirkwood - Cancer 2010 cited by 186

  23. Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21

    Authors: Darren R. Shafren, Gough G. Au, Tam Nguyen, Nicole G. Newcombe, Erin S. Haley, Leone Beagley, Emil Johansson, Peter Hersey, Richard D. Barry - Clinical Cancer Research 2004 cited by 155

  24. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, James Larkin, Paul Lorigan, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Thierry Lesimple, Michele Maio, Gerald P. Linette, Laurent Mortier, Inge Marie Svane, Jacob Schachter, Michael P. Brown, Peter Hersey, Catherine Barrow, Ragini R. Kudchadkar, Caroline Dutriaux, Xinni Song, Pietro Quaglino, Paola Queirolo, Friedegund Meier, Daniil Stroyakovskiy, B. Guillot, Pablo L. Ortiz‐Romero, Lars Bastholt, Claus Garbe, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Carmen Loquai, Frank Meiß, Vanna Chiarion‐Sileni, Gil Bar‐Sela, Bernard M. Fitzharris, Philippe Saïag, Jean‐Philippe Arnault, Jan‐Christoph Simon, Rosalie Stephens, Jean‐François Baurain, Célèste Lebbé, P. Combemale, Reinhard Dummer, Axel Hauschild, Phillip Parente, Naoya Yamazaki, Mohammed Milhem, M.‐T. Leccia, L. Geoffrois, Lutz Kretschmer, Elaine Dunwoodie, John Walker, Michal Lotem, Daniel Hendler, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Marcin Dzienis, Geke A.P. Hospers, Marco Siano, Jessica C. Hassel, Philippa Corrie, Maria-Jose Passos, Max Levin, Christoph Höeller, L. Machet, Sigrun Hallmeyer, Ashita Waterston, V. Descamps, Felix Kiecker, Maureen J.B. Aarts, Henrik Schmidt and 34 more - The Lancet Oncology 2021 cited by 72